retatrutide 4mg ESC 2024: improves lipid and cardiovascular risk profile in Phase II trial Triple G 4 mg (Retatrutyd)

Phase 2 NEJM titration (still common in research) Phase 2 retatrutide titration schedule Phase Initiation Weeks Weeks 1-4 Weekly Dose 1 mg Phase Early escalation Weeks Weeks 5-8 Weekly Dose 2 mg Phase Mid escalation Weeks Weeks 9-12 Weekly Dose 4 mg Phase High escalation Weeks Weeks 13-16 Weekly Dose 8 mg Phase Maximum Weeks Weeks 17+ Weekly Dose 12 mg Source: Jastreboff et al., NEJM 2023

This makes the ServoPen a sustainable choice for ongoing GLP-1 treatment, particularly in regions where cost effectiveness and long-term adherence are priorities

Will I have to go to court? Most cases settle without trial

Retatrutide is not commercially available